&lt;p&gt;LncRNA EMX2OS, Regulated by TCF12, Interacts with FUS to Regulate the Proliferation, Migration and Invasion of Prostate Cancer Cells Through the cGMP-PKG Signaling Pathway&lt;/p&gt;

Wang, Zhiqiang; Zhang, Chaowei; Chang, Junkai; Tian, Xin; C, Zhu; Xu, Weihua

doi:10.2147/ott.s243552

Cited by 26 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, another study implied that focal adhesion was related to tumor occurrence and metastasis (Eke and Cordes, 2015). Wang et al (2020) found that the cGMP-PKG signaling pathway also has a tight relationship with proliferation, migration, and invasion in PCa.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) is the most common malignant male neoplasm in the American male population. Our prior studies have demonstrated that protein phosphatase 1 regulatory subunit 12A (PPP1R12A) could be an efficient prognostic factor in patients with PCa, promoting further investigation. The present study attempted to construct a gene signature based on PPP1R12A and metabolism-related genes to predict the prognosis of PCa patients.MethodsThe mRNA expression profiles of 499 tumor and 52 normal tissues were extracted from The Cancer Genome Atlas (TCGA) database. We selected differentially expressed PPP1R12A-related genes among these mRNAs. Tandem affinity purification-mass spectrometry was used to identify the proteins that directly interact with PPP1R12A. Gene set enrichment analysis (GSEA) was used to extract metabolism-related genes. Univariate Cox regression analysis and a random survival forest algorithm were used to confirm optimal genes to build a prognostic risk model.ResultsWe identified a five-gene signature (PPP1R12A, PTGS2, GGCT, AOX1, and NT5E) that was associated with PPP1R12A and metabolism in PCa, which effectively predicted disease-free survival (DFS) and biochemical relapse-free survival (BRFS). Moreover, the signature was validated by two internal datasets from TCGA and one external dataset from the Gene Expression Omnibus (GEO).ConclusionThe five-gene signature is an effective potential factor to predict the prognosis of PCa, classifying PCa patients into high- and low-risk groups, which might provide potential novel treatment strategies for these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Protective roles of this lncRNA were also found and validated in classical papillary thyroid cancer 22 , prostate cancer 23 . The role of EMX2OS in hypoxia was also reported in myalgic encephalomyelitis/chronic fatigue syndrome by Yang et al 24 .…”

Section: Discussionmentioning

confidence: 74%

Identification of a hypoxia-associated long non-coding RNA signature and nomogram as a prognostic target for clear cell renal cell carcinoma

Chen¹,

Pan²,

Jin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background To develop a hypoxia-associated long non-coding (lncRNA) signature for risk stratification in clear cell renal cell carcinoma (ccRCC). Methods The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA KIRC) dataset was downloaded and analyzed. Results Four prognostic hypoxia-associated lncRNAs were used for signature construction. The four lncRNAs were downregulated in high grade, advanced stage, and high-risk ccRCC. ccRCC patients in the high-risk group had a worse prognosis than those in the low-risk group. And the risk score was significantly higher in high grade and advanced stage. The signature had an independent and long-standing prognosis prediction ability up to 10-year follow-up. Notably, the risk score was significantly positively correlated with the infiltration abundances of six immune cells from the Tumor IMmune Estimation Resource (TIMER). The gene set enrichment analysis (GSEA) also suggested that the signature was involved in the metabolism and tumorigenesis, which were closely related to the hypoxic tumor microenvironment. Ultimately, a nomogram was built to predict the individual long-term survival possibility. Conclusions We have developed a new hypoxia-associated lncRNA signature, representing a promising tool for risk stratification tool in ccRCC. It might serve as a prognostic index to facilitate personalized counseling for treatment.

show abstract

“…EMX2OS, an enhancer RNA, was upregulated in low-risk ccRCC and significantly associated with low-grade, early stage, and favorable prognosis (27). Protective roles of this lncRNA were also found and validated in classical papillary thyroid cancer (28) and prostate cancer (29). The role of EMX2OS in hypoxia was also reported in myalgic encephalomyelitis/chronic fatigue syndrome by Yang et al (30).…”

Section: Discussionmentioning

confidence: 79%

Identification of a Four Hypoxia-Associated Long Non-Coding RNA Signature and Establishment of a Nomogram Predicting Prognosis of Clear Cell Renal Cell Carcinoma

et al. 2021

View full text Add to dashboard Cite

To identify novel hypoxia-associated long non-coding RNAs (lncRNAs) as potential biomarkers, we developed a risk stratification signature and constructed a prognosis prediction nomogram of clear cell renal cell carcinoma (ccRCC). Hypoxia-related lncRNAs were identified through Pearson correlation analysis between the expression profiles of hypoxia-related differentially expressed genes and lncRNAs from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) dataset. Then, a signature of four key lncRNAs (COMETT, EMX2OS, AC026462.3, and HAGLR) was developed. The four lncRNAs were downregulated in high-grade, advanced stage, and high-risk ccRCC. The signature had an independent and long-standing prognosis prediction ability up to a 10-year follow-up. Notably, the risk score was significantly positively correlated with the infiltration abundances of six immune cells from the Tumor IMmune Estimation Resource (TIMER). The gene set enrichment analysis (GSEA) also suggested that the signature was involved in metabolism and tumorigenesis, which were closely related to the hypoxic tumor microenvironment. Ultimately, a nomogram of signature, age, stage, and grade, was built to predict the individual long-term survival possibility. Finally, the expressions of four lncRNAs were validated by quantitative real-time PCR (qRT-PCR). Our study identified a four-lncRNA signature and established a prognostic nomogram that reliably predicts survival in ccRCC. The findings may be beneficial to therapeutic customization and medical decision-making.

show abstract

<p>LncRNA EMX2OS, Regulated by TCF12, Interacts with FUS to Regulate the Proliferation, Migration and Invasion of Prostate Cancer Cells Through the cGMP-PKG Signaling Pathway</p>

Cited by 26 publications

References 34 publications

Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer

Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer

Identification of a hypoxia-associated long non-coding RNA signature and nomogram as a prognostic target for clear cell renal cell carcinoma

Identification of a Four Hypoxia-Associated Long Non-Coding RNA Signature and Establishment of a Nomogram Predicting Prognosis of Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About